28.11

0.02% +0.005

Royalty Pharma plc (RPRX)

Overview News Price History Option Chain Discussions Forecast Dividend History

Royalty Pharma plc stock is currently priced at $28.11, with a 24-hour trading volume of 832.32K. It has seen a +0.02% increased in the last 24 hours and a -7.00% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $27.99 pivot point. If it approaches the $28.33 resistance level, significant changes may occur.

Previous Close:

$28.11

Open:

$27.98

24h Volume:

832.32K

Market Cap:

$12.58B

Revenue:

$2.35B

Net Income/Loss:

$1.13B

P/E Ratio:

249.91

EPS:

0.1125

Net Cash Flow:

$2.99B

1W Performance:

-0.16%

1M Performance:

-7.00%

6M Performance:

+3.17%

1Y Performance:

-19.88%

1D Range:

$27.81

$28.27

52W Range:

$25.92

$35.76

Royalty Pharma plc Stock (RPRX) Company Profile

Name

Royalty Pharma plc

Sector

Healthcare (1203)

Industry

Biotechnology (688)

Phone

212 883 0200

Address

110 East 59th Street, Floor 33, New York, NY

Employee

Twitter

Next Earnings Date

2024-05-09

Latest SEC Filings

RPRX's Discussions on Twitter

Royalty Pharma plc Stock (RPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-14-22	Resumed	UBS	Buy
May-13-22	Initiated	Scotiabank	Sector Outperform
Apr-27-22	Initiated	Goldman	Buy
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight
Apr-06-22	Resumed	Morgan Stanley	Overweight
Oct-29-21	Upgrade	Citigroup	Neutral → Buy
Jul-30-21	Initiated	Tigress Financial	Buy
Nov-09-20	Upgrade	UBS	Neutral → Buy
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	BofA Securities	Buy
Jul-13-20	Initiated	Citigroup	Neutral
Jul-13-20	Initiated	Cowen	Outperform
Jul-13-20	Initiated	Goldman	Neutral
Jul-13-20	Initiated	JP Morgan	Neutral
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight
Jul-13-20	Initiated	SunTrust	Buy
Jul-13-20	Initiated	UBS	Neutral

View All

Royalty Pharma plc Stock (RPRX) Latest News

Royalty Pharma (RPRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months

The Motley Fool

Royalty Pharma plc Stock (RPRX) Financials Data

Royalty Pharma plc (RPRX) Revenue 2024

RPRX reported a revenue (TTM) of $2.35 billion for the quarter ending December 31, 2023, a +5.24% rise year-over-year.

Royalty Pharma plc (RPRX) Net Income 2024

RPRX net income (TTM) was $1.13 billion for the quarter ending December 31, 2023, a +2,550% increase year-over-year.

Royalty Pharma plc (RPRX) Cash Flow 2024

RPRX recorded a free cash flow (TTM) of $2.99 billion for the quarter ending December 31, 2023, a +39.36% increase year-over-year.

Royalty Pharma plc (RPRX) Earnings per Share 2024

RPRX earnings per share (TTM) was $2.52 for the quarter ending December 31, 2023, a +869.47% growth year-over-year.

Royalty Pharma plc Stock (RPRX) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
RIGGS RORY B	Director	Jan 03 '24	Sale	27.79	199,098	5,532,276	55,801
RIGGS RORY B	Director	Jan 02 '24	Sale	28.52	235,200	6,707,081	254,899
Avara Management Ltd	10% Owner	Dec 29 '23	Sale	28.04	65,803	1,845,406	2,477,520
Avara Management Ltd	10% Owner	Dec 28 '23	Sale	28.20	209,863	5,918,934	2,543,323
Avara Management Ltd	10% Owner	Dec 27 '23	Sale	28.01	41,729	1,168,754	2,753,186
Avara Management Ltd	10% Owner	Dec 15 '23	Sale	28.01	10,229	286,499	2,794,915
Avara Management Ltd	10% Owner	Dec 14 '23	Sale	28.91	364,441	10,534,276	2,805,144
Avara Management Ltd	10% Owner	Dec 13 '23	Sale	28.95	307,935	8,916,012	3,169,585
Coyne Terrance P.	EVP & CFO	Aug 10 '23	Sale	30.75	37,500	1,153,091	790,000
Coyne Terrance P.	EVP & CFO	Aug 09 '23	Sale	30.72	37,500	1,151,936	827,500

Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in the identification, evaluation, and acquisition of royalties and royalty-related assets on various biopharmaceutical therapies. The company collaborates with innovators from academic institutions, research hospitals, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and three development-stage product candidates. It has royalties on various therapeutic areas and drug classes, including Neulasta, Neupogen, Rituxan, Imbruvica, Trodelvy, Tazverik, and Xtandi in oncology; Lyrica in neuropathic pain; Biktarvy, Genvoya, Prezista, Symtuza, Truvada, and Atripla in HIV; Humira, Remicade, and Cimzia TNF inhibitors; Kalydeco, Orkambi, Symdeko, and Trikafta in cystic fibrosis; Tecfidera and Tysabri in multiple sclerosis; Emgality, Nurtec ODT (rimegepant), and vazegepant in migraine; and others. The company was founded in 1996 and is based in New York, New York.